Clinical Trial Update: A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 study evaluating nivolumab plus docetaxel versus placebo plus docetaxel in men with advanced castration-resistant prostate cancer has posted results in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-07-22